PUBLICATIONS
MDMA-assisted therapy is associated with a reduction in chronic pain among people with post-traumatic stress disorder
Frontiers in Psychiatry
Increasing evidence demonstrates 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy (MDMA-AT) may be a safe and effective treatment for post-traumatic stress disorder (PTSD). There is growing interest in MDMA-AT to address a range of other health challenges.
The Therapeutic Uses of Psilocybin and MDMA for Pandemic-Related Mental Health Problems
Frontiers in Psychiatry
Stigma and limited treatment options have amounted to substantial unmet need and violations in human rights for people with mental health disorders. Looking ahead, heightened post-pandemic demand for mental healthcare signifies an urgent need to bolster clinical capacity by integrating novel, cost-effective approaches into existing systems.
Psychedelic use is associated with reduced daily opioid use among people who use illicit drugs in a Canadian setting
Science Direct
Research into the therapeutic and naturalistic uses of psychedelics for improving outcomes related to mental health disorders has generated increasing interest in recent years. While controlled clinical trials of psychedelics have signaled benefits for treating substance use disorders, this area has not been well studied in the context of naturalistic psychedelic use. This study sought to investigate the possible relationship between recent naturalistic psychedelic use and subsequent daily illicit opioid use among people who use drugs (PWUD).
Safety considerations in the evolving legal landscape of psychedelic‑assisted psychotherapy
BioMed Central
International drug policy is rapidly evolving in tandem with promising evidence for psychedelic-assisted psychotherapy (PAP) in treating a range of mental health conditions. Canada is among the countries increasingly expanding access to psychedelic substances for therapeutic purposes.